Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38216005/
Owing to the dysregulation of protein kinase activity in many diseases including cancer, this enzyme family has become one of the most important drug targets in the 21st century. There...
This review highlights 80 FDA-approved small molecule protein kinase inhibitors, detailing their physicochemical properties and emphasizing seven newly approved drugs in 2023 for cancer and inflammatory diseases.
Share
Dynamic findings of brain magnetic resonance imaging in a haploidentical hematopoietic stem cell transplantation recipient with cytomegalovirus ventriculoencephalitis: a case report and systematic review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39372409/
Our case demonstrated unique cytomegalovirus (CMV) encephalitis post-haploidentical donor hematopoietic stem cell transplantation (HID-HSCT), with early findings on diffusion-weighted brain magnetic resonance imaging (MRI) in the absence of any neurologic...
A 54-year-old man developed cytomegalovirus encephalitis post-haploidentical stem cell transplant, diagnosed via MRI and CSF NGS, highlighting the need for early detection and improved treatment strategies in HSCT patients.
Share
Transient Myeloproliferative Disorder (TMD), Acute Lymphoblastic Leukemia (ALL), and Juvenile Myelomonocytic Leukemia (JMML) in a Child with Noonan Syndrome: Sequential Occurrence, Single Center Experience, and Review of the Literature - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39336782/
Noonan syndrome (NS) is an autosomal dominant disorder that varies in severity and can involve multiple organ systems. In approximately 50% of cases, it is caused by missense mutations in...
This case report highlights a child with Noonan syndrome developing transient myeloproliferative disorder, hyperdiploid BCP-ALL, and later juvenile myelomonocytic leukemia, emphasizing hematological complications associated with NS.
Share
Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38186333/
Inotuzumab ozogamicin (InO) is a CD22-directed antibody conjugated with calicheamicin. The phase IB of the ITCC-059 trial tested InO combined with chemotherapy in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL)....
The ITCC-059 trial evaluated inotuzumab ozogamicin with chemotherapy in pediatric relapsed/refractory BCP-ALL, establishing a recommended phase II dose of 1.8 mg/m²/cycle, with an 80% response rate.
Share
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39179671/
Aberrant expression of HOX and MEIS1 family genes, as seen in KMT2A-rearranged, NUP98-rearranged, or NPM1-mutated leukemias leads to arrested differentiation and leukemia development. HOX family genes are essential gatekeepers of...
Aberrant HOX and MEIS1 gene expression in specific leukemias leads to differentiation arrest. Menin inhibitors show promise in treating these conditions, prompting collaborative international efforts for clinical trials in pediatric populations.
Share